AUSTAR Group is a technology-based pharmaceutical engineering solution provider operating in over 50 countries and regions, collaborating with leading pharmaceutical companies to advance human health. With a team of over 1000 professionals worldwide, the company offers technically guaranteed pharmaceutical engineering solutions, aiding clients in establishing drug production facilities and enhancing global drug safety and efficacy. The company's expertise encompasses a wide array of pharmaceutical technology, including Clean Utilities, Pharmaceutical Automation & Digitalization, Biopharma Process & Technology, Regulatory Compliance & Operation Excellence, and more. AUSTAR's global presence is supported by technical experts, professional equipment production sites, and an experienced engineering execution team, ensuring strong technical R&D, quality-assured equipment manufacture, and efficient project management and execution. Founded in 1991 in Hong Kong, with its headquarters in Beijing, PRC, AUSTAR Group was listed on the Main Board of the Stock Exchange of Hong Kong Limited in 2014 (Stock code: 6118). The company's diverse portfolio includes renowned business and product brands such as BIOSYSTEC, STERIS-AUSTAR, ROTA-AUSTAR, Pharma LeanTec, Pharma LeanDigital, AUSMILL, Aunity, and Purvita. AUSTAR Group's presence in the Health Care and Pharmaceutical industries, along with its extensive technical capabilities and global reach, positions the company as an impactful player in advancing pharmaceutical engineering solutions and contributing to the overall betterment of global healthcare.
There is no investment information
No recent news or press coverage available for AUSTAR Group.
We care about your data, and we'd love to use cookies make your experience better.
